{"disease":{"id":"metastatic-well-differentiated-neuroendocrine-neoplasm","name":"metastatic well differentiated neuroendocrine neoplasm"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03453489","title":"AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Barbara Ann Karmanos Cancer Institute","has_results":true},{"nct_id":"NCT03001349","title":"68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors","phase":"EARLY_PHASE1","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}